100 related articles for article (PubMed ID: 18089965)
1. Cancer after renal transplantation.
Vasudev B; Hariharan S
Curr Opin Nephrol Hypertens; 2007 Nov; 16(6):523-8. PubMed ID: 18089965
[TBL] [Abstract][Full Text] [Related]
2. Malignancy after transplantation.
Buell JF; Gross TG; Woodle ES
Transplantation; 2005 Oct; 80(2 Suppl):S254-64. PubMed ID: 16251858
[TBL] [Abstract][Full Text] [Related]
3. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
4. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
5. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
[TBL] [Abstract][Full Text] [Related]
6. Post transplant Kaposi's sarcoma among Nigerians: a report of two cases.
Abdu A; Adamu B; Sani MU; Mohammed AZ; Alhassan SU; Borodo MM
Afr J Med Med Sci; 2005 Dec; 34(4):395-8. PubMed ID: 16752672
[TBL] [Abstract][Full Text] [Related]
7. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
Schwartz JJ; Ishitani MB; Weckwerth J; Morgenstern B; Milliner D; Stegall MD
Transplantation; 2007 Sep; 84(6):715-21. PubMed ID: 17893604
[TBL] [Abstract][Full Text] [Related]
8. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
9. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
10. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
11. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Yakupoglu YK; Buell JF; Woodle S; Kahan BD
Transplant Proc; 2006 Mar; 38(2):358-61. PubMed ID: 16549120
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction.
Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A
Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
16. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
17. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
[TBL] [Abstract][Full Text] [Related]
18. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
19. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
20. The kidney transplant program at the Bergamo Center.
Remuzzi G; Perico N; Gotti E; Ruggenenti P; Rota G; Locatelli G
Clin Transpl; 2000; ():179-91. PubMed ID: 11512311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
